Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
US Department of Justice
Federal Trade Commission
Express Scripts
Deloitte
Novartis
Julphar
Moodys
Dow

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,268,489

« Back to Dashboard

Which drugs does patent 6,268,489 protect, and when does it expire?


Patent 6,268,489 protects ZITHROMAX and ZMAX and is included in seven NDAs. There has been one Paragraph IV challenge on Zithromax.

This patent has sixty-eight patent family members in forty-two countries.

Summary for Patent: 6,268,489

Title: Azithromycin dihydrate
Abstract:Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.
Inventor(s): Allen; Douglas J. M. (New London, CT), Nepveux; Kevin M. (Old Saybrook, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:07/994,040
Patent Claim Types:
see list of patent claims
Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
ZITHROMAX
azithromycin
FOR SUSPENSION;ORAL050710-001Oct 19, 1995ABRXYesNo► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
FOR SUSPENSION;ORAL050710-002Oct 19, 1995ABRXYesYes► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
TABLET;ORAL050711-001Jul 18, 1996ABRXYesNo► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
TABLET;ORAL050730-001Jun 12, 1996ABRXYesYes► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
INJECTABLE;INJECTION050733-001Jan 30, 1997APRXYesYes► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
TABLET;ORAL050784-001May 24, 2002ABRXYesNo► Subscribe► SubscribeY
Pfizer
ZITHROMAX
azithromycin
FOR SUSPENSION;ORAL050693-001Sep 28, 1994RXYesYes► Subscribe► SubscribeY
Pf Prism Cv
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 2005RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,268,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/US87/01612Jul 09, 1987

International Patent Family for Patent: 6,268,489

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)44► Subscribe
African Regional IP Organization (ARIPO)8800093► Subscribe
Argentina243532► Subscribe
Austria71370► Subscribe
Austria72446► Subscribe
Australia1883988► Subscribe
Australia604553► Subscribe
Bosnia and Herzegovina98213► Subscribe
Bulgaria47348► Subscribe
Canada1310642► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Accenture
Cantor Fitzgerald
Fuji
Argus Health
Colorcon
US Department of Justice
Daiichi Sankyo
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot